New drug combo trial offers hope for rare immune disorder
NCT ID NCT07187167
Summary
This study is testing whether a combination of two existing drugs, lenalidomide and dexamethasone, can help control Rosai-Dorfman disease, a rare disorder where the immune system causes tissue damage. The trial will enroll 40 adults with the condition to see how well the treatment works and how safe it is. Participants will take the medications in repeating cycles for about one year while doctors track their progress.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROSAI-DORFMAN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.